2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aminoacyl-tRNA Synthetase

Aminoacyl-tRNA Synthetase

tRNA Synthetase, aaRS

Aminoacyl-tRNA Synthetase

Related Products

PDF 0.17 MB

Aminoacyl-tRNA synthetases (AARSs) are the enzymes that catalyze the aminoacylation reaction by covalently linking an amino acid to its cognate tRNA in the first step of protein translation. In mammals, AARSs usually exist in free form or in the form of a multi-tRNA synthetase complex (MSC), and the latter consists of eight AARSs and three non-enzymatic AARS-interacting multi-functional proteins (AIMP1/p43, AIMP2/p38, and AIMP3/p18).

AARSs are responsible for the proper pairing of codons on mRNA with amino acids. AARSs are also involved in RNA splicing, transcriptional regulation, translation, and other aspects of cellular homeostasis. Study of these enzymes is of great interest to the researchers due to its pivotal role in the growth and survival of an organism. AARSs are one of the leading targets for developing novel anti-infective agents. Further, unfolding the interesting structural and functional aspects of these enzymes in the last few years has qualified them as a potential drug target against various diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0958
    Mupirocin
    		Inhibitor 98.01%
    Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis.
    Mupirocin
  • HY-12479A
    Epetraborole hydrochloride
    		Inhibitor 99.62%
    Epetraborole (GSK2251052) hydrochloride is a novel leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole hydrochloride can be used in multidrug-resistant gram-negative pathogens infection research.
    Epetraborole hydrochloride
  • HY-136265
    BC-LI-0186
    		Inhibitor 99.20%
    BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research.
    BC-LI-0186
  • HY-W014233
    L-Histidinol dihydrochloride
    		Inhibitor ≥98.0%
    L-Histidinol dihydrochloride is an orally active histidyl-tRNA synthetase inhibitor. L-Histidinol dihydrochloride interferes with the initiation stage of protein synthesis, thus affecting cell proliferation and metabolism. L-Histidinol dihydrochloride has the effect of modulating the sensitivity of tumor cells to chemotherapeutic agents. L-Histidinol dihydrochloride reduces the toxicity of certain chemotherapeutic agents to normal tissues and enhance the sensitivity of tumor cells to chemotherapeutic agents.
    L-Histidinol dihydrochloride
  • HY-108900
    Leu-AMS
    		Inhibitor 98.08%
    Leu-AMS (compound 6), a leucine analogue, is a potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC50 of 22.34 nM, which inhibits the catalytic activity of LRS but did not affect the leucine-induced mTORC1 activation. Leu-AMS shows cytotoxicity in cancer cells and normal cells, and inhibits the growth of bacteria.
    Leu-AMS
  • HY-112860
    Asp-AMS
    		Inhibitor 98.67%
    Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme.
    Asp-AMS
  • HY-108940
    GlyRS-IN-1
    		Inhibitor 99.40%
    GlyRS-IN-1 is a glycyl-tRNA synthase (GlyRS) inhibitor extracted from patent WO 2017066459 A1. GlyRS-IN-1 can also inhibit the growth of bacteria.
    GlyRS-IN-1
  • HY-112862
    Arg-AMS
    		Inhibitor ≥98.0%
    Arg-AMS (compound 24) is a potent nanomolar inhibitor of arginyl tRNA synthetase, which displays tightly bound inhibitory characteristics for the A-domains in non-ribosomal peptide synthetases (NRPS) enzymes.
    Arg-AMS
  • HY-112861
    Gln-AMS
    		Inhibitor 99.21%
    Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes.
    Gln-AMS
  • HY-108939
    Aminoacyl tRNA synthetase-IN-1
    		Inhibitor 99.80%
    Aminoacyl tRNA synthetase-IN-1 is a bacterial aminoacyl tRNA synthetase (aaRS) inhibitor. Aminoacyl tRNA synthetase-IN-1 has inhibitory activity against S. aureus, E. faecalis and E.coli.
    Aminoacyl tRNA synthetase-IN-1
  • HY-126130
    LysRs-IN-2
    		Inhibitor 99.92%
    LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with IC50s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase (PfKRS) and Cryptosporidium parvum lysyl-tRNA synthetase (CpKRS), respectively.
    LysRs-IN-2
  • HY-W108875
    Mupirocin lithium
    		Inhibitor
    Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis.
    Mupirocin lithium
  • HY-163540
    NP-BTA
    		Inhibitor 99.15%
    NP-BTA is an allosteric inhibitor for glutaminyl-tRNA synthetase (GlnRS). NP-BTA exhibits antifungal efficacy against Candida albicans, with MIC50 of 6.25 μM.
    NP-BTA
  • HY-112861A
    Gln-AMS TFA
    		Inhibitor 99.65%
    Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 µM.
    Gln-AMS TFA
  • HY-136431
    BC-DXI-843
    		Inhibitor 99.76%
    BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer.
    BC-DXI-843
  • HY-103280
    LysRs-IN-1
    		Inhibitor 98.64%
    LysRs-IN-1 is a Lysyl-tRNA synthetase (LysRs) inhibitor.
    LysRs-IN-1
  • HY-150719
    AIMP2-DX2-IN-1
    		≥98.0%
    AIMP2-DX2-IN-1 (Compound 35) is a potent AIMP2-DX2 inhibitor with an IC50 of 0.1063 μM.
    AIMP2-DX2-IN-1
  • HY-159628A
    Glu-AMS TEA
    		Inhibitor
    Glu-AMS TEA is a competitive inhibitor of Escherichia coli glutamyl-tRNA synthetase (GluRS), with the Ki of 2.8 nM.
    Glu-AMS TEA
  • HY-P990782
    Efzofitimod
    		99.29%
    Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD).
    Efzofitimod
  • HY-12479
    Epetraborole
    		Inhibitor
    Epetraborole (GSK2251052) is a leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole can be used in multidrug-resistant gram-negative pathogens infection research.
    Epetraborole
Cat. No. Product Name / Synonyms Application Reactivity